Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.59 |
| ▸ | F12 | P00748 | 2/20 | 0.59 |
| ▸ | PLAU | P00749 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17323238 | 0.86 | NPC1 (0.57) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL19675588 | 0.82 | NPC1 (0.53) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL17321504 | 0.82 | NPC1 (0.53) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL2800393 | 0.82 | F2 (0.58) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL2787324 | 0.78 | NPC1 (0.76) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL5035110 | 0.78 | NR1H2 (0.55) | F2F12NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31331972 | 0.77 | NPC1 (0.69) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL21777016 | 0.76 | SMN1; SMN2 (0.66) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL8311588 | 0.74 | SMN1; SMN2 (1.00) | F2F12PLAUNPC1RAB9A | |
| SCHEMBL2251038 | 0.73 | NPC1 (1.00) | F2F12PLAUNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628971-B1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-7223780-B2 | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1628971-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | disclosed |
| US-20050009827-A1 | Carboxamide derivatives of 1,2,3- and 1,2,4-triazoles and 1H- and 2H-tetrazoles, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-pyrrol-1-yl-1H-[1,2,4]triazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101555-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479679-A1 | Triazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009827-A1 | Carboxamide derivatives of 1,2,3- and 1,2,4-triazoles and 1H- and 2H-tetrazoles, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-pyrrol-1-yl-1H-[1,2,4]triazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | TFPI, F11, TFPI2 | F2 4/4885F12 8/4885PLAU 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.